Concepedia

Early on-treatment C-reactive protein and its kinetics predict survival and response in recurrent and/or metastatic head and neck cancer patients receiving first-line pembrolizumab

Markus Haas, Alexander Lein, Thorsten Fuereder, Julia Schnoell, Faris F. Brkic, David T. Liu, Lorenz Kadletz‐Wanke, Gregor Heiduschka, Bernhard J. Jank

Investigational New Drugs · 2023 · 12 citations · 20 references

DOIFull text

Open access

Abstract

On-treatment CRP was identified as a prognostic biomarker for objective response and survival in R/M HNSCC patients receiving first-line pembrolizumab and could be easily incorporated into clinical practice as a widely available and cost-effective biomarker.

References

20

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 28.6K citations

, , +9

Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016

Theo Vos, Amanuel Alemu Abajobir, Kalkidan Hassen Abate et al. · The Lancet · 2017 · 13.3K citations · Full text

Index for rating diagnostic tests

W. J. Youden · Cancer · 1950 · 11.1K citations · Full text

, , +6

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Barbara Burtness, Kevin J. Harrington, Richard Greil et al. · The Lancet · 2019 · 3K citations · Full text

, , +7

Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012

Ranee Mehra, Tanguy Y. Seiwert, Shilpa Gupta et al. · British Journal of Cancer · 2018 · 443 citations · Full text